FDA rejects Scholar Rock's apitegromab application due to facility issues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Scholar Rock (SRRK) PT Lowered to $48 at Leerink Partners
September 24, 2025 4:15 AM EDTLeerink Partners analyst Mani Foroohar lowered the price target on Scholar Rock (NASDAQ: SRRK) to $48.00 (from $51.00) while maintaining a Outperform rating.
The analyst comments " Following the CRL for apitegromab this morning (here), we update our model with more conservative launch assumptions to reflect ongoing uncertainty on... More
